|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
McCrea PD, Maher MT and Gottardi CJ:
Nuclear signaling from cadherin adhesion complexes. Curr Top Dev
Biol. 112:129–196. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Broussard JA, Getsios S and Green KJ:
Desmosome regulation and signaling in disease. Cell Tissue Res.
360:501–512. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Aktary Z, Kulak S, Mackey J, Jahroudi N
and Pasdar M: Plakoglobin interacts with the transcription factor
p53 and regulates the expression of 14-3-3σ. J Cell Sci.
126:3031–3042. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chidgey M and Dawson C: Desmosomes: A role
in cancer? Br J Cancer. 96:1783–1787. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Simcha I, Geiger B, Yehuda-Levenberg S,
Salomon D and Ben-Ze'ev A: Suppression of tumorigenicity by
plakoglobin: An augmenting effect of N-cadherin. J Cell Biol.
133:199–209. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Aktary Z, Alaee M and Pasdar M: Beyond
cell-cell adhesion: Plakoglobin and the regulation of tumorigenesis
and metastasis. Oncotarget. 8:32270–32291. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Alaee M, Nool K and Pasdar M: Plakoglobin
restores tumor suppressor activity of p53R175H mutant by
sequestering the oncogenic potential of β-catenin. Cancer Sci.
109:1876–1888. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Huang L, Ji H, Yin L, Niu X, Wang Y, Liu
Y, Xuan Q, Li L, Zhang H, Zhou X, et al: High expression of
plakoglobin promotes metastasis in invasive micropapillary
carcinoma of the breast via tumor cluster formation. J Cancer.
10:2800–2810. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Aktary Z, Chapman K, Lam L, Lo A, Ji C,
Graham K, Cook L, Li L, Mackey JR and Pasdar M: Plakoglobin
interacts with and increases the protein levels of metastasis
suppressor Nm23-H2 and regulates the expression of Nm23-H1.
Oncogene. 29:2118–2129. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Barker N and Clevers H: Catenins, Wnt
signaling and cancer. Bioessays. 22:961–965. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Besnier LS, Cardot P, Da Rocha B, Simon A,
Loew D, Klein C, Riveau B, Lacasa M, Clair C, Rousset M and Thenet
S: The cellular prion protein PrPc is a partner of the Wnt pathway
in intestinal epithelial cells. Mol Biol Cell. 26:3313–3328. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Miravet S, Piedra J, Miró F, Itarte E,
García de Herreros A and Duñach M: The transcriptional factor Tcf-4
contains different binding sites for β-catenin and plakoglobin. J
Biol Chem. 277:1884–1891. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Winn RA, Bremnes RM, Bemis L, Franklin WA,
Miller YE, Cool C and Heasley LE: Gamma-Catenin expression is
reduced or absent in a subset of human lung cancers and
re-expression inhibits transformed cell growth. Oncogene.
21:7497–7506. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Korc M: Role of growth factors in
pancreatic cancer. Surg Oncol Clin N Am. 7:25–41. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Polireddy K and Chen Q: Cancer of the
pancreas: Molecular pathways and current advancement in treatment.
J Cancer. 7:1497–1514. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ji B, Tsou L, Wang H, Gaiser S, Chang DZ,
Daniluk J, Bi Y, Grote T, Longnecker DS and Logsdon CD: Ras
activity levels control the development of pancreatic diseases.
Gastroenterology. 137:1072–1082. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Krah NM, De La O JP, Swift GH, Hoang CQ,
Willet SG, Chen Pan F, Cash GM, Bronner MP, Wright CV, MacDonald RJ
and Murtaugh LC: The acinar differentiation determinant PTF1A
inhibits initiation of pancreatic ductal adenocarcinoma. Elife. Jul
7–2015.(Epub ahead of print). doi: 10.7554/eLife.07125. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lee AYL, Dubois CL, Sarai K, Zarei S,
Schaeffer DF, Sander M and Kopp JL: Cell of origin affects tumour
development and phenotype in pancreatic ductal adenocarcinoma. Gut.
Jan 23–2018.(Epub ahead of print). doi:
10.1136/gutjnl-2017-314426.
|
|
20
|
Jones S, Zhang X, Parsons DW, Lin JC,
Leary RJ, Angenendt P, Mankoo P, Carter H, Kamiyama H, Jimeno A, et
al: Core signaling pathways in human pancreatic cancers revealed by
global genomic analyses. Science. 321:1801–1806. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Karanikas M, Esempidis A, Chasan ZT,
Deftereou T, Antonopoulou M, Bozali F, Amarantidis K and Man YG:
Pancreatic cancer from molecular pathways to treatment opinion. J
Cancer. 7:1328–1339. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Long J, Liu Z, Wu X, Xu Y and Ge C: Gene
expression profile analysis of pancreatic cancer based on
microarray data. Mol Med Rep. 13:3913–3919. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
McCleary-Wheeler AL, McWilliams R and
Fernandez-Zapico ME: Aberrant signaling pathways in pancreatic
cancer: A two compartment view. Mol Carcinog. 51:25–39. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Preis M and Korc M: Signaling pathways in
pancreatic cancer. Crit Rev Eukaryot Gene Expr. 21:115–129. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Mohelnikova-Duchonova B, Oliverius M,
Honsova E and Soucek P: Evaluation of reference genes and
normalization strategy for quantitative real-time PCR in human
pancreatic carcinoma. Dis Markers. 32:203–210. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bustin SA, Benes V, Garson JA, Hellemans
J, Huggett J, Kubista M, Mueller R, Nolan T, Pfaffl MW, Shipley GL,
et al: The MIQE guidelines: Minimum information for publication of
quantitative Real-Time PCR experiments. Clin Chem. 55:611–622.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Pfaffl MW, Horgan GW and Dempfle L:
Relative expression software tool (REST) for group-wise comparison
and statistical analysis of relative expression results in
real-time PCR. Nucleic Acids Res. 30:e362002. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Croft D, O'Kelly G, Wu G, Haw R, Gillespie
M, Matthews L, Caudy M, Garapati P, Gopinath G, Jassal B, et al:
Reactome: A database of reactions, pathways and biological
processes. Nucleic Acids Res. 39:D691–D697. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Mi H, Guo N, Kejariwal A and Thomas PD:
PANTHER version 6: Protein sequence and function evolution data
with expanded representation of biological pathways. Nucleic Acids
Res. 35:D247–D252. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Knudsen KA and Wheelock MJ: Plakoglobin,
or an 83-kD homologue distinct from beta-catenin, interacts with
E-cadherin and N-cadherin. J Cell Biol. 118:671–679. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Rubinfeld B, Souza B, Albert I, Munemitsu
S and Polakis P: The APC protein and E-cadherin form similar but
independent complexes with alpha-catenin, beta-catenin, and
plakoglobin. J Biol Chem. 270:5549–5555. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Aktary Z and Pasdar M: Plakoglobin
represses SATB1 expression and decreases in vitro proliferation,
migration and invasion. PLoS One. 8:e783882013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Rozengurt E, Sinnett-Smith J and Kisfalvi
K: Crosstalk between insulin/insulin-like growth factor-1 receptors
and G protein-coupled receptor signaling systems: A novel target
for the antidiabetic drug metformin in pancreatic cancer.
ClinCancer Res. 16:2505–2511. 2010.
|
|
34
|
Bryant KL, Mancias JD, Kimmelman AC and
Der CJ: KRAS: Feeding pancreatic cancer proliferation. Trends
Biochem Sci. 39:91–100. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Posch C and Ortiz-Urda S: NRAS mutant
melanoma-undrugable? Oncotarget. 4:494–495. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Troiani T, Martinelli E, Capasso A,
Morgillo F, Orditura M, De Vita F and Ciardiello F: Targeting EGFR
in pancreatic cancer treatment. Curr Drug Targets. 13:802–810.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Bruns CJ, Solorzano CC, Harbison MT, Ozawa
S, Tsan R, Fan D, Abbruzzese J, Traxler P, Buchdunger E, Radinsky R
and Fidler IJ: Blockade of the epidermal growth factor receptor
signaling by a novel tyrosine kinase inhibitor leads to apoptosis
of endothelial cells and therapy of human pancreatic carcinoma.
Cancer Res. 60:2926–2935. 2000.PubMed/NCBI
|
|
38
|
Morgan MA, Parsels LA, Kollar LE, Normolle
DP, Maybaum J and Lawrence TS: The combination of epidermal growth
factor receptor inhibitors with gemcitabine and radiation in
pancreatic cancer. Clin Cancer Res. 14:5142–5149. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Pan H, Gao F, Papageorgis P, Abdolmaleky
HM, Faller DV and Thiagalingam S: Aberrant activation of
gamma-catenin promotes genomic instability and oncogenic effects
during tumor progression. Cancer Biol Ther. 6:1638–1643. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Cohen S, Lee D, Zhai B, Gygi SP and
Goldberg AL: Trim32 reduces PI3K-Akt-FoxO signaling in muscle
atrophy by promoting plakoglobin-PI3K dissociation. J Cell Biol.
204:747–758. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Roy SK, Srivastava RK and Shankar S:
Inhibition of PI3K/AKT and MAPK/ERK pathways causes activation of
FOXO transcription factor, leading to cell cycle arrest and
apoptosis in pancreatic cancer. J Mol Signal. 5:102010. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Spindler V, Dehner C, Hübner S and Waschke
J: Plakoglobin but not desmoplakin regulates keratinocyte cohesion
via modulation of p38MAPK signaling. J Invest Dermatol.
134:1655–1664. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Heidenreich KA and Kummer JL: Inhibition
of p38 mitogen-activated protein kinase by insulin in cultured
fetal neurons. J Biol Chem. 271:9891–9894. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Sweeney G, Somwar R, Ramlal T, Volchuk A,
Ueyama A and Klip A: An inhibitor of p38 mitogen-activated protein
kinase prevents insulin-stimulated glucose transport but not
glucose transporter translocation in 3T3-L1 adipocytes and L6
myotubes. J Biol Chem. 274:10071–10078. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Li Y, Yu WH, Ren J, Chen W, Huang L,
Kharbanda S, Loda M and Kufe D: Heregulin targets gamma-catenin to
the nucleolus by a mechanism dependent on the DF3/MUC1 oncoprotein.
Mol Cancer Res. 1:765–775. 2003.PubMed/NCBI
|
|
46
|
Fabre-Lafay S, Monville F, Garrido-Urbani
S, Berruyer-Pouyet C, Ginestier C, Reymond N, Finetti P, Sauvan R,
Adélaïde J, Geneix J, et al: Nectin-4 is a new histological and
serological tumor associated marker for breast cancer. BMC Cancer.
7:732007. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Derycke MS, Pambuccian SE, Gilks CB,
Kalloger SE, Ghidouche A, Lopez M, Bliss RL, Geller MA, Argenta PA,
Harrington KM and Skubitz AP: Nectin 4 overexpression in ovarian
cancer tissues and serum: Potential role as a serum biomarker. Am J
Clin Pathol. 134:835–845. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Zhu WY, Hunag YY, Liu XG, He JY, Chen DD,
Zeng F, Zhou JH and Zhang YK: Prognostic evaluation of CapG,
Gelsolin, P-gp, GSTP1, and Topo-II Proteins in non-small cell lung
cancer. Anat Rec (Hoboken). 295:208–214. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Gocheva V and Joyce JA: Cysteine
cathepsins and the cutting edge of cancer invasion. Cell Cycle.
6:60–64. 2007. View Article : Google Scholar : PubMed/NCBI
|
